LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in LENZ Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +11 vs. Q4 2024
- Shares held
- 21.1M
- +1.23M (+6.2%) vs. Q4 2024
- Total value
- $541.8M
- −$30.8M (−5.4%) vs. Q4 2024
- New holders
- 24
- 30 more added
- Sold out
- 13
- 27 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LENZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 145 | $197.3M |
| Q1 2026 | 146 | $303.3M |
| Q4 2025 | 161 | $561.6M |
| Q3 2025 | 166 | $1.36B |
| Q2 2025 | 114 | $725.1M |
| Q1 2025 | 105 | $541.8M |
| Q4 2024 | 95 | $573.2M |
| Q3 2024 | 78 | $444.8M |
| Q2 2024 | 65 | $327.0M |
| Q1 2024 | 55 | $362.0M |
| Q4 2023 | 63 | $81.5M |
| Q3 2023 | 67 | $75.8M |
| Q2 2023 | 66 | $81.2M |
| Q1 2023 | 62 | $72.9M |
| Q4 2022 | 66 | $95.6M |
| Q3 2022 | 63 | $93.9M |
| Q2 2022 | 63 | $83.0M |
| Q1 2022 | 63 | $185.7M |
| Q4 2021 | 58 | $431.7M |
| Q3 2021 | 60 | $587.4M |
| Q2 2021 | 51 | $981.4M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding LENZ Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,166,517 | $30.0M | 0.00% | +10,892+0.9% | Added |
| Vanguard Group Inc | 1,199,462 | $30.8M | 0.00% | +21,015+1.8% | Added |
| Paradigm Biocapital Advisors LP | 1,511,932 | $38.9M | 1.79% | +741,477+96.2% | Added |
| Falcon Edge Capital, LP | 3,612,211 | $92.9M | 41.37% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,178,823 | $107.4M | 1.79% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −149,502−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −39,746−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −25,366−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −17,716−100.0% | Sold out |
| BML Capital Management, LLC | 0 | $0 | 0.00% | −9,271−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −8,385−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −7,938−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −7,447−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −5,458−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −2,309−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −278−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | 0 | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |